Navigation Links
Anadys Pharmaceuticals to Present at Two Upcoming Investor Conferences
Date:9/3/2009

SAN DIEGO, Sept. 3 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS) announced today that it will present at the Thomas Weisel Partners Healthcare Conference on Thursday, September 10, 2009 at 3:15 p.m. EDT (12:15 p.m. PDT). The conference is being held at the Four Seasons Hotel in Boston. Steve Worland, Ph.D., President and Chief Executive Officer of Anadys, will provide an overview of Anadys and its clinical development programs, ANA598 and ANA773.

Dr. Worland will also present at the Rodman & Renshaw Annual Global Investment Conference on Friday, September 11, 2009 at 11:15 a.m. EDT (8:15 a.m. PDT). The conference is being held at the New York Palace Hotel in New York City.

Each presentation will be webcast at the time of presentation and can be accessed on the Investor Relations page of the Company's website at www.anadyspharma.com. Listeners are encouraged to visit the website approximately five minutes prior to each presentation to download or install any necessary software. A replay of the presentations will be available approximately one hour after the live webcasts conclude and will be available through September 25, 2009.

About Anadys

Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines for the treatment of hepatitis C. The Company believes hepatitis C represents a large unmet medical need in which meaningful improvements in treatment outcomes may be attainable with the introduction of new medicines. The Company is developing ANA598, a non-nucleoside polymerase inhibitor for the treatment of hepatitis C. The Company has also investigated the potential of ANA773, an oral, small-molecule inducer of endogenous interferons that acts via the Toll-like receptor 7, or TLR7, pathway in hepatitis C.

Safe Harbor Statement

Statements in this press release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, references to Anadys' strategy, development programs, and ability to develop novel medicines for the treatment of hepatitis C. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause Anadys' actual results to be materially different from historical results or from any results expressed or implied by such forward-looking statements. For example, the results of preclinical and early clinical studies may not be predictive of future results, and Anadys cannot provide any assurances that ANA598 or ANA773 will not have unforeseen safety issues, will have favorable results in future clinical trials or will receive regulatory approval. Risk factors that may cause actual results to differ are more fully discussed in Anadys' SEC filings, including Anadys' Form 10-K for the year ended December 31, 2008 and Anadys' Form 10-Q for the quarter ended June 30, 2009. All forward-looking statements are qualified in their entirety by this cautionary statement. Anadys is providing this information as of this date and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.


'/>"/>
SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Anadys Pharmaceuticals, Inc. Announces Pricing of Common Stock and Warrant Offering
2. Anadys Pharmaceuticals to Present at the Citi Biotech Day
3. Anadys Pharmaceuticals Reports Fourth Quarter and Year-End 2008 Financial Results and Highlights
4. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
5. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
6. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
7. Anadys Pharmaceuticals to Present at Bio Investor Forum
8. Anadys Pharmaceuticals to Present at BIO InvestorForum 2007
9. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
10. Steven Holtzman Joins Satori Pharmaceuticals Board of Directors
11. Endo Pharmaceuticals Introduces VALSTAR(TM) (Valrubicin) To Fill Unmet Need In Aggressive Form of Bladder Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... ... Rob Lowe acts as host and helps educate and inform the public using the ... can reconnect with America as it explores some of the best places to hike ... an inventive new place for a family vacation, and have discovered hiking. Many will ...
(Date:5/26/2017)... ... May 26, 2017 , ... “Just What Happened in the Garden of Eden”: retells the stories ... Eden” is the creation of published author, Penelope Colt, mother, trader, horse farmer, artist and ... NYC when she was three. At six, they moved to Dayton, Ohio, where Penny ...
(Date:5/24/2017)... ... 2017 , ... Dr. Alan I. Benvenisty, MD is dual board certified in ... known for his distinguished expertise and experience in the diagnosis and treatment of vascular ... treating renovascular disease and aortic aneurysm . He is known for his minimally ...
(Date:5/24/2017)... ... 2017 , ... Patients who want to receive cosmetic dentistry procedures such as ... Bedich for a consultation, with or without a referral. Dr. Bedich enjoys improving the ... , Dr. Bedich offers a variety of cosmetic dentistry services at his practice ...
(Date:5/24/2017)... ... 2017 , ... Medic CE , a Career Step company, is sponsoring ... hosted by the Journal of Emergency Medical Services (JEMS). The free webinar, to be ... by Captain Rommie Duckworth, LP, a career fire captain as well as founder and ...
Breaking Medicine News(10 mins):
(Date:5/9/2017)... PORTLAND, Ore. , May 9, 2017 /PRNewswire/ ... company that provides technology solutions to improve the ... reported financial results for the first quarter ended ... that our products enable our customers to identify ... them to intervene before events like heart attacks ...
(Date:5/6/2017)...  May is Stroke Awareness Month and Omron Healthcare ... methods to prevent a stroke: monitor and manage your ... and Prevention, undetected and uncontrolled hypertension is a leading ... leader in personal heart health technology, recently evolved its ... and stroke and is advancing a national public education ...
(Date:5/4/2017)... Clarius Mobile Health, a digital healthcare ... this week at the American Congress of Obstetricians ... San Diego, CA from May ... perfect tool for clinicians to easily confirm pregnancy, ... pregnancy-related complications like ectopic pregnancy and placenta previa," ...
Breaking Medicine Technology: